LAVAL, Québec, Canada | Jan 9, 2006 | BioSyntech, Inc. (“BioSyntech” or the “Company”) (TSX-V: BSY) announced today that BST-CarGel is the subject of a study published in The Journal of Bone and Joint Surgery (JBJS, American Volume). The paper, entitled “Chitosan-Glycerol Phosphate/Blood Implants Improve Hyaline Cartilage Repair in Ovine Microfracture Defects”appears in the December issue (2005;87:2671-2686) of JBJS Am, which is widely acknowledged as the most highly regarded clinical orthopaedic journal.

The study describes the ability of BST-CarGel to repair damaged cartilage in the knees of sheep.  “Detailed animal studies such as ours are extremely valuable because they permit in-depth scientific assessments of both the quality of the repair and its underlying mechanisms, information that is very difficult to obtain in human studies,” said Dr. Caroline Hoemann, a senior researcher in the Department of Chemical Engineering and Institute of Biomedical Engineering at Ecole Polytechnique of Montreal, and the first author of the paper. “BST-CarGel demonstrated statistically superior cartilage repair compared to the control, due to novel mechanisms which have not been previously observed.”

In addition to this publication, two presentations at the upcoming 6^th Symposium of the International Cartilage Repair Society (ICRS) held during January 8-11, 2006, will describe recent work completed with BST-CarGel, and will be given by Dr. Hoemann as well as Dr. Michael Buschmann, also of Ecole Polytechnique. This year, Dr. Buschmann is a symposium invitee serving as both a keynote lecturer and a presenter at the Cartilage Repair Think Tank sponsored by the American Orthopaedic Society for Sports Medicine, which will convene prior to the symposium. 

BST-CarGel is currently being tested in a multicenter, randomized clinical trial being carried out in . The data from this pivotal trial will support Canadian and European product approvals, and may be instrumental in gaining regulatory approval in the .